Reddy’s Laboratories Ltd. and Bayer announced that the two companies have entered into a partnership for the marketing and distribution of a second brand of Vericiguat in India. Under the terms of this agreement, Bayer granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra. In India, Vericiguat, a soluble guanylate cyclase (sGC) stimulator, is indicated, as an adjunct to guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction (less by 45%), following a recent worsening of heart failure requiring hospitalization or taking intravenous (IV) diuretics on an outpatient basis.
Vericiguat acts on a pathway not currently targeted by existing heart failure treatments and may reduce the combined risk of cardiovascular death and heart failure hospitalization in these patients. India has between 8 and 10 million people suffering from heart failure, making it one of the populations most affected by this disease.
2024-04-05 21:14:58
#Bayer #Reddys #sign #marketing #distribution #agreement #Vericiguat #brand #India
